| |
Newsroom /
Business
/
Business
/
Managing Clinical Investigator Compensation
Managing Clinical Investigator Compensation
Establishing transparent and defensible compensation processes for clinical investigators not only saves money - it is absolutely essential in today's restrictive pharma landscape. Regulatory groups, legislative bodies and consumer advocacy groups are applying relentless pressure on commercial relationships with physicians, altering and often limiting industry practices.
Navi Mumbai,
Maharashtra,
India
(prbd.net)
02/11/2010
Improve cost-effectiveness of investigator compensation - and ensure compliance.
Establishing transparent and defensible compensation processes for clinical investigators not only saves money - it is absolutely essential in today's restrictive pharma landscape. Regulatory groups, legislative bodies and consumer advocacy groups are applying relentless pressure on commercial relationships with physicians, altering and often limiting industry practices. Now the ripple effect is hitting clinical operations. Some investigations in the area have garnered public attention, with more bound to follow.
Cutting Edge Information projects that within five years the same regulatory scrutiny currently on the commercial side will expand to the clinical side. Companies that do not recognize this inevitable reality and formalize their FMV processes today put themselves at great risk for compromised trial results, an audit, financial damage and regulatory scrutiny. Diligence and constant monitoring will go a long way to preventing careless errors and courting potentially dangerous consequences.
Managing Clinical Investigator Compensation gives your company what it needs to be proactive and prepare for change while avoiding common pitfalls. CEI surveyed more than 50 companies of all types and sizes, across 13 different therapeutic areas, for the most up-to-date compensation rates for clinical investigators. For the most comprehensive analysis, CEI compiled and analyzed data from companies' clinical operations as well as primary investigators.
Use the data benchmarks to:
• Control costs
• Establish current, market based payments to investigators
• Develop regulation-proof calculation and documentation methods
• Stay current on the latest FMV regulation concerns and trends
Companies Included in Report
The surveyed companies provided primary information either in the form of survey data or a telephone interview. Cutting Edge Information's analysts use secondary data to supplement the information provided by study participants. Responding companies include five top 20 and 10 Top 50 pharmaceutical companies, as well as biotechnology companies, medical device firms and third-party providers.
Therapeutic Areas Included in Report
• Autoimmune
• Cardiology and Thrombosis
• CNS/Psychology
• Dermatology
• Endocrinology
• Gastroenterology
• Hematology
• Infectious Diseases
• Medical Devices
• Musculoskeletal
• Oncology
• Respiratory
• Women's Health
Metrics Included in Report
Managing Clinical Investigator Compensation's three chapters include compensation data collected from clinical investigators as well as pharmaceutical, biotechnology and medical device companies. Data include breakdowns by phase, therapeutic area and experience.
Investigator Compensation: Industry Data
• Percentage of time that companies monitor negotiations between CROs and investigators
• Percentage of companies that hire CROs to recruit investigators
• Percentage of companies that hire CROs to contract investigators
• Percentage of time that CROs handle investigator payments
• Percentage of companies with a formal process in place for determining investigator compensation
• Percentage of companies that allow primary investigators to concurrently lead clinical trials for other companies
• Average years of experience required for primary investigators, by phase
• Average years of experience required for primary investigators, by company type and by phase
Articles Published and Speeches Delivered
• Percentage of companies whose criteria for primary investigators include published articles
• Average number of published journal articles required of primary investigators, by phase
• Percentage of companies with investigator compensation limits in place
• Average number of total site fees by phase
• Average number of investigators per site, by phase
For more information kindly visit
http://www.bharatbook.com/detail.asp?id=100598&rt=Managing-Clinical-Investigator-Compensation.html
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
About
Bharat Book Bureau is the leading business information aggregator providing market research reports and online databases. Bharatbook is also into the business of marketing conferences worldwide and undertakes custom research.
|